Eytan Breman

464 total citations
24 papers, 336 citations indexed

About

Eytan Breman is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Eytan Breman has authored 24 papers receiving a total of 336 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 17 papers in Immunology and 7 papers in Molecular Biology. Recurrent topics in Eytan Breman's work include CAR-T cell therapy research (21 papers), Immune Cell Function and Interaction (13 papers) and Immunotherapy and Immune Responses (7 papers). Eytan Breman is often cited by papers focused on CAR-T cell therapy research (21 papers), Immune Cell Function and Interaction (13 papers) and Immunotherapy and Immune Responses (7 papers). Eytan Breman collaborates with scholars based in Belgium, United States and Netherlands. Eytan Breman's co-authors include Caroline Lonez, Matteo Rossi, David E. Gilham, Frédéric Lehmann, Sophie Agaugué, Bikash Verma, Marco L. Davila, David A. Sallman, Jason Brayer and Elizabeth M. Sagatys and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Eytan Breman

24 papers receiving 320 citations

Peers

Eytan Breman

ONCOL

IMMUN

GENET

Erik Alcantar-Orozco Belgium

Annie Etuk United Kingdom

Veronica Valtolina Italy

Chris Martin United States

Silvia Arcangeli Italy

Edward Waldron United States

Haolong Lin China

Dana Stenger Germany

Beatrice Claudia Cianciotti Italy

Nils W. Engel Germany

Erik Alcantar-Orozco Belgium

Eytan Breman

260 ×0.9

ONCOL

172 ×1.1

IMMUN

88 ×0.7

70 ×1.0

GENET

54 ×0.8

Citations per year, relative to Eytan Breman Eytan Breman (= 1×) peers Erik Alcantar-Orozco

Countries citing papers authored by Eytan Breman

Since Specialization

Citations

This map shows the geographic impact of Eytan Breman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eytan Breman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eytan Breman more than expected).

Fields of papers citing papers by Eytan Breman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eytan Breman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eytan Breman. The network helps show where Eytan Breman may publish in the future.

Co-authorship network of co-authors of Eytan Breman

This figure shows the co-authorship network connecting the top 25 collaborators of Eytan Breman. A scholar is included among the top collaborators of Eytan Breman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eytan Breman. Eytan Breman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Pollyea, Daniel A., Tessa Kerre, Dries Deeren, et al.. (2025). Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia. Leukemia. 39(12). 2907–2915. 1 indexed citations

Lonez, Caroline, et al.. (2025). Clinical Proof-of-Concept of a Non-Gene Editing Technology Using miRNA-Based shRNA to Engineer Allogeneic CAR T-Cells. International Journal of Molecular Sciences. 26(4). 1658–1658. 8 indexed citations

Bolsée, Jennifer, et al.. (2025). Tandem CAR T-cells targeting CD19 and NKG2DL can overcome CD19 antigen escape in B-ALL. Frontiers in Immunology. 16. 1557405–1557405. 5 indexed citations

Lonez, Caroline & Eytan Breman. (2024). Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?. Cells. 13(2). 146–146. 48 indexed citations

Rossi, Matteo & Eytan Breman. (2024). Engineering strategies to safely drive CAR T-cells into the future. Frontiers in Immunology. 15. 1411393–1411393. 25 indexed citations

Bolsée, Jennifer, et al.. (2023). 232 NKG2D-based multi-specific CAR T-cells to overcome antigen escape and improve anti-tumor efficacy. SHILAP Revista de lepidopterología. A267–A267. 1 indexed citations

Rossi, Matteo, Mikhail Steklov, Thuy Nguyen, et al.. (2023). Efficient shRNA-based knockdown of multiple target genes for cell therapy using a chimeric miRNA cluster platform. Molecular Therapy — Nucleic Acids. 34. 102038–102038. 13 indexed citations

Lonez, Caroline, et al.. (2023). 285 Proof-of-concept of a non-gene editing technology using shRNA down-regulation to engineer and optimize CAR T-cell functionality. SHILAP Revista de lepidopterología. A326–A326. 4 indexed citations

Steklov, Mikhail, et al.. (2021). 146 Evolving Mutliplexed shRNA to generate tailored CAR T cell therapy. SHILAP Revista de lepidopterología. A154–A154. 1 indexed citations

10.

Breman, Eytan, Amélie I. Velghe, Thùy Linh Nguyễn, et al.. (2021). 107 Armoring NKG2D CAR T cells with IL-18 improves in vivo anti-tumor activity. SHILAP Revista de lepidopterología. A118–A118. 4 indexed citations

11.

Deeren, Dries, Johan Maertens, Tara L. Lin, et al.. (2021). Co-Expression of an shRNA Targeting MICA/Micb Improves the Clinical Activity of a NKG2D-Based CAR T in Patients with Relapsed / Refractory AML/MDS. Blood. 138(Supplement 1). 408–408. 10 indexed citations

12.

Prenen, Hans, Jeroen Dekervel, Alain Hendlisz, et al.. (2021). Updated data from alloSHRINK phase I first-in-human study evaluating CYAD-101, an innovative non-gene edited allogeneic CAR-T in mCRC.. Journal of Clinical Oncology. 39(3_suppl). 74–74. 32 indexed citations

13.

Gilham, David E., et al.. (2020). Single vector multiplexed shRNA provides a non-gene edited strategy to concurrently knockdown the expression of multiple genes in CAR T cells.. Journal of Clinical Oncology. 38(15_suppl). 3103–3103. 1 indexed citations

14.

Cutsem, Eric Van, J.-P. Machiels, Marc Van den Eynde, et al.. (2019). Phase 1 studies assessing the safety and clinical activity of autologous and allogeneic NKG2D-based CAR-T therapy in metastatic colorectal cancer. Annals of Oncology. 30. iv124–iv125. 13 indexed citations

15.

Breman, Eytan, et al.. (2018). Overcoming Target Driven Fratricide for T Cell Therapy. Frontiers in Immunology. 9. 2940–2940. 30 indexed citations

16.

Sallman, David A., Jason Brayer, Elizabeth M. Sagatys, et al.. (2018). NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient. Haematologica. 103(9). e424–e426. 63 indexed citations

17.

Gilham, David E., et al.. (2018). TCR inhibitory molecule as a promising allogeneic NKG2D CAR-t cell approach.. Journal of Clinical Oncology. 36(15_suppl). e15042–e15042. 9 indexed citations

18.

Sallman, David A., Tessa Kerre, Xavier Poiré, et al.. (2018). Remissions in Relapse/Refractory Acute Myeloid Leukemia Patients Following Treatment with NKG2D CAR-T Therapy without a Prior Preconditioning Chemotherapy. Blood. 132(Supplement 1). 902–902. 20 indexed citations

19.

Ruben, Jurjen M., Gina Stella García-Romo, Eytan Breman, et al.. (2017). Human plasmacytoid dendritic cells acquire phagocytic capacity by TLR9 ligation in the presence of soluble factors produced by renal epithelial cells. Kidney International. 93(2). 355–364. 14 indexed citations

20.

Breman, Eytan, Dirk M. van der Steen, Mirjam H.M. Heemskerk, et al.. (2014). HLA Monomers as a Tool to Monitor Indirect Allorecognition. Transplantation. 97(11). 1119–1127. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact